News

CYNK-101 has previously been granted fast track and orphan drug designation.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Mustang Bio plans to add more clinical trial sites in the near future.

Nilanjan Ghosh, MD, PhD, discussed the impact of liso-cel's approval.

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed a new partnership with Nationwide Children’s Hospital.

In preclinical studies, OBX-115 demonstrated improved TIL persistence, potency, and tumor control compared with unengineered TILs.

Data is expected in the first quarter of 2023 for both Stargardt disease and retinitis pigmentosa.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed current studies evaluating gene therapies in hemophilia.

Reported efficacy data included a WOMAC score reduction at 6 months following a single dose.

Most patients treated with FLT180a had elevated FIX levels over 2 years after treatment.

The chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.

Recent long-term data from the phase 2 extension has also demonstrated CAP-1002's efficacy in Duchenne.

Review top news and interview highlights from the week ending July 22, 2022.

The gene therapy received a positive CHMP opinion in May 2022.

Upstaza has been granted marketing authorization by the European Commission.

Robin Shaw, MD, PhD, Professor of Medicine at the University of Utah and Director of the Nora Eccles Harrison Cardiovascular Research and Training Institute, shared his thoughts on the program.

WU-CART-007 has been granted fast track, rare pediatric disease, and orphan drug designations.

The principal investigator of the HOPE-2 trial discussed results of the trial in the non-ambulatory population of patients with Duchenne muscular dystrophy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Ofra-vec continues to be evaluated in phase 2 trials for glioblastoma and colorectal cancer.

The professor of neurosurgery at Rush University Medical School discussed data seen in the phase 1/2 clinical trial of LCTOPC1.

Ultragenyx also exercised its option to acquire GeneTx, its partner in developing GTX-102.

PLX-PAD is also being studied for the treatment of steroid-refractory chronic graft versus host disease.

The professor and head of coagulation disorders and Comprehensive Care Centre, University Hospital of Frankfurt, Germany, discussed future integration of EtranaDez into hemophilia B treatment.

Rajesh Pahwa, MD, FANA, FAAN, discussed balancing hope with current challenges with stem cell approaches in PD.

Genetics is the future of heart failure and cardiomyopathy treatment, Judge told CGTLive in an interview.

The associate professor from UC San Diego discussed promising efficacy and safety data from a phase 1/2 trial.

Lauren Veltri, MD Director, WVU Cancer Institute Hematopoietic Malignancy and Cellular Therapy Program, discussed the recent FACT accreditation.